Biotechnology careers in India: what the numbers say about jobs, growth and where to start

Biotechnology is the discipline flat that nearly all Indian pupil has heard of and nearly nobody can depict as an industry. It has a national bioeconomy fig quoted in all speech, a fistful of companies that most group have never looked up, a national exam all year, and a startup environment that raised a lot of prosperity in 2022 and much small since. That blend produces a lot of assured direction and extremely small arithmetic.

This study answers three questions alongside numbers that can be checked: which part of the field is really growing, what all job optimises for, and which skills the field is currently abbreviated of. Everything below comes from BIRAC and authorities releases, authoritative exam reports, business filings and published regulations, alongside the duration stated. Start alongside the one-page brief.

1. Why appearance at this field at all

Four things create biotechnology value a grave look, and one should provision you pause.

It is one of India's fastest-growing measured industries. India's bioeconomy reached US$195.3 billion in 2025, concerning 4.8% of GDP, according to the India BioEconomy Report 2026 prepared by ABLE for the Department of Biotechnology's BIRAC and released on 19 March 2026. It grew concerning 18% in one twelvemonth and has additional than doubled since 2020. It was approximately US$10 milliard in 2014.

It hires through national exams, on a published timetable. 26,808 candidates registered for the GATE 2026 Biotechnology document and 83,546 registered for Life Sciences in the June 2026 sequence of the Joint CSIR-UGC NET. A applicant can peruse the syllabus, the cutoff and the fellowship amount before deciding to prepare. Few research-heavy sectors are this transparent concerning their admission gate.

It has genuine manufacturing anchors, not fair laboratories. Biocon earned ₹16,927 crore in FY26, and the curate of discipline and innovation stated in September 2026 that India accounts for nearly 60% of earth vaccine manufacturing by volume. That is a ministerial assertion fairly than a published dataset, but the companies rearward it, Serum Institute, Bharat Biotech and Biological E, are among the largest employers of biotechnology graduates in the country.

Public prosperity is moving, and it is moving towards manufacturing. The Union Budget 2026-27 announced Biopharma SHAKTI, ₹10,000 crore complete five years for biologics and biosimilars, according to a PIB backgrounder. The BioE3 guideline has already funded 17 shared biomanufacturing facilities. Announced prosperity is the closest item this field has to a hiring forecast.

And the caution: personal prosperity is lean and export rules are in flux. Venture backing into Indian life-sciences startups was US$269 million in 2024, downward from a highest of US$749 myriad in 2022. The United States now charges a 100% tariff on patented drugs. A field can develop 18% in a twelvemonth and motionless be a difficult location to discover a archetypal job if you aim at the incorrect part of it.

2. How big it is, and how accelerated it is really growing

Start alongside a difference that separates group who have peruse concerning this field from group who comprehend it. You volition see one figure quoted in nearly all part on Indian biotechnology: a US$300 milliard bioeconomy by 2030. That is a government target. A distinct NITI Aayog roadmap published in July 2026 carries a projection of concerning US$392 milliard by 2030, built on industry modelling. Neither has been measured. Quoting either as although it describes the field today is the fastest way to endure an interviewer.

What has really been compiled is the annual bioeconomy evaluation itself, published all March by BIRAC alongside the industry affiliation ABLE. It put the field at US$195.3 billion in 2025, and the sequence runs US$137 milliard in 2022, US$151.1 milliard in 2023 and US$165.7 milliard in 2024. Treat it as a careful evaluation assembled from business and section data, not as an audited figure akin GDP.

The second compiled thing, and the additional crucial one for a career, is the form of the sector. India does not have one biotechnology industry. It has four extremely distinct businesses under one name, and all hires distinct people.

If you are asked how big Indian biotechnology is, provision what was compiled and the year: “US$195.3 milliard in 2025, concerning 4.8% of GDP, according to the India BioEconomy Report 2026”. If you are asked concerning the US$300 milliard figure, say what it is: a authorities mark for 2030, not a measurement. Answering the archetypal inquiry alongside the second figure is the inform that you have memorised a header fairly than peruse a report.

The third item value knowing is direction, and current the sequence is small gentle than the headlines suggest. Growth was concerning 29% in 2022, concerning 10% in 2023 and 9.7% in 2024, before jumping to concerning 18% in 2025. The 2024 slowdown is uncomplicated to miss, and it is the logic the 2025 fig was greeted as a improvement fairly than a regular year.

There is a fourth movement underneath, and it is the one that changes anywhere the jobs are. The figure of registered biotech startups rosy to 11,855 in 2025 from 10,075 a twelvemonth before and 8,531 in 2023. Startup arrangement kept rising equal during project backing fell, which method more, smaller companies competing for small prosperity each.

3. Who leads, who is stuck, and what that tells you

This is the most helpful array in the study if you are choosing an employer, and it starts alongside a fact that surprises nearly everyone. The largest listed biotechnology business in India, Biocon, earned ₹16,927 crore in FY26. The next seven listed names in this study earned concerning ₹13,660 crore between them. One business is larger than the remainder of its listed equal collection combined.

The logic is structural: the largest vaccine makers in India, Serum Institute, Bharat Biotech and Biological E, are privately held, and most biotech startups are too small to report. What follows is the organised, reported part of the sector, affirmative the privately held companies whose numbers are community through filings or ranking reports. Treat it as a map of anywhere expert hiring happens, not as a measure of the sector's size.

Two patterns are value carrying into any conversation concerning this sector. The archetypal is that scale and border have separated. Praj earned ₹3,168 crore and kept concerning 4.8% of it as EBITDA. Anthem earned ₹2,124 crore and reported an EBITDA border of 43.4%. Revenue tells you extremely small current concerning the health of the endeavor you would be joining.

The second is that the client matters additional than the science. Sai Life Sciences grew 29% and doubled gain doing betterment and manufacturing activity for earth medication companies. Syngene does akin work, grew 2.7% and saw gain autumn 36%, mostly since a sole ample biologics client reduced its orders. That divide, between who pays you and how many of them there are, runs through the remainder of this report.

4. Where the growth really sits

Here is the form that matters most for anyone joining. In FY26 the biotechnology businesses that grew fastest were not the ones alongside the best-known brands. They were the ones marketing betterment and manufacturing capability to a broad set of earth customers, and the ones whose own products were in expanding categories specified as biosimilars and enzymes.

Averaging those groups makes the item and additionally its limit. The three agreement investigation businesses grew concerning 16% between them, the three biopharma and component businesses concerning 4%, and the two manufacturing businesses concerning 8%. But the dispersed inner all collection is wider than the gap between groups. This is not a narrative concerning fine segments and bad segments. It is a narrative concerning how many customers a endeavor has and how cyclical their petition is.

Underneath the companies, the largest sole origin of new prosperity in the field is public. The BioE3 policy, approved by the Cabinet on 24 August 2024, had received complete 2,000 proposals by July 2026 and recommended complete 270 projects, according to a government answer in Parliament. Its archetypal call for shared pilot-scale facilities, called BioEnablers, funded 17 biomanufacturing facilities, and 15 Bio-AI hubs have been recommended. On top of that sits Biopharma SHAKTI, ₹10,000 crore complete five years for biologics and biosimilars, alongside a stated goal of a 5% portion of the earth biopharma market.

“Who is the client for the activity this squad does, and how many of them are there?” Almost no applicant asks it. If the answer is a sole ample client, your project can disappear alongside one agreement decision, as Syngene established in FY26. If it is the company's own product, you volition be measured on regulatory milestones and initiate dates. If it is a grant, you volition be measured on publications and deliverables. Those are three extremely distinct jobs inner what looks akin the identical industry.

5. How a finding reaches a patient, a site or a factory, and the jobs that do it

Indian biotechnology does not have one path from lab to market. It has four, operating at extremely distinct scales, and nearly all entry-level function sits inner one of them. Knowing which one you are applying to explains most of what the job volition really awareness like.

The admission pipeline into the archetypal of those is enormous, and unusually for an Indian industry it is counted in community all twelvemonth through the national exams.

Four conditions run through all conversation in this sector, and candidates routinely get them wrong. Biosimilar is a biologic medication shown to be extremely akin to an already approved citation biologic, and it is not the identical as a generic, which is a chemically identical copy of a small-molecule drug. CRDMO is a agreement research, betterment and manufacturing organisation, a business that does this activity for person else's product. GMP is fine manufacturing practice, which in India is set out in the revised Schedule M of the Drugs Rules. Bioeconomy is the total value of biotechnology-based action in a year, and in India it is reported for calendar years by BIRAC and ABLE.

6. The startup boom, and the correction that followed it

This is the part of the field that changed fastest, and the part anywhere most students' mental example is three years out of date. Venture backing into Indian life-sciences startups peaked at US$749 million in 2022. By 2024 it was US$269 million, according to a study by Omnivore and Nucleate covered by Business Today. That is value seeing plainly before you build a occupation scheme about a startup.

The clearest sole example of anywhere the business act moved arrived on 20 March 2026, whenever the Indian patent on semaglutide, the energetic component in the best-known GLP-1 diabetes and weight-loss drugs, expired. Within weeks about a dozen Indian companies, including Dr Reddy's, Sun, Zydus, Lupin and Torrent, launched about twenty brands, alongside prices starting at concerning ₹1,290 a duration according to a six-month count by BioPharma APAC. In April 2026 generics already accounted for fractional of the ₹88 crore Indian semaglutide market. Almost no applicant strolling into an discussion can explain why this mattered, and it changes the answer to “where is Indian biopharma going”.

The innovation narrative did not halt whenever the backing slowed. It moved into community programmes. The Genome India project sequenced 10,074 individuals throughout 99 communities and released the data on 9 January 2025. In May 2025 ICAR released two genome-edited grain varieties, DRR Dhan 100 (Kamala) and Pusa DST Rice 1, which the authorities described as the world's first, according to All India Radio.And in July 2026 BIRAC was reported to have selected its archetypal seven or eight biotech startups for backing under the ₹1 lakh crore RDI scheme.

The occupation point. Laboratory and manufacturing roles motionless transport the overwhelming bulk of the jobs, and it is anywhere most group should start. But the roles that merge existence discipline alongside item else, norm systems, regulatory writing, procedure scale-up or data, are the ones currently abbreviated of people. That is since they were created faster than any university started training for them.

7. How the prosperity is made, and what you volition be measured on

This division exists for one reason. Whatever function you obtain in biotechnology, your activity volition be judged by how it moves one of four blocks. People who can name the obstacle they power get promoted noticeably faster than group who cannot.

The figure the field is judged on is the EBITDA margin, and the dispersed throughout comparable Indian biotechnology businesses in FY26 is extraordinary. Companies that all depict themselves as biotechnology create margins that differ by a aspect of nine.

Read that array as a alert concerning a sole word. Biotechnology describes a set of techniques, not a endeavor model. A business that owns a hard-to-make product, specified as a fermentation-based ingredient, can acquire a border complete 30%. A business that sells engineering projects built on the identical discipline can acquire under 5%. The skills transfer between them, but the force on your squad does not.

Two lines deserve precision since they form day-to-day work. Batch achievement rate is the portion of manufacturing runs that continue all norm test, and in biologics manufacturing a sole unsuccessful lot can disbursal weeks of output. Capacity utilisation is the portion of a facility's accessible manufacturing period that is really sold, and in a agreement endeavor it is the figure most closely tied to margin. If you associate a CRDMO, anticipate to comprehend concerning utilisation lengthy before you comprehend concerning revenue.

8. What is being built, and where

Announced prosperity is the closest item this field has to a hiring forecast, and unusually for a science-based industry, most of it is community and published. The Department of Biotechnology's own prosperity for 2026-27 is ₹3,446 crore, basically flat on the year, of which its umbrella Bio-RIDE scheme takes ₹2,300 crore. The larger commitments sit exterior that line.

The sole largest dedication is not in the biotechnology prosperity at all. The Research Development and Innovation scheme, approved by the Cabinet on 1 July 2025, sets up a ₹1 lakh crore corpus to backing personal research. On 8 October 2026 it approved its archetypal 19 prosperity managers, alongside ₹7,131 crore committed, according to Analytics India Magazine. BIRAC is among the channels, and its archetypal biotech selections were reported in July 2026. For anyone considering a startup career, that is the largest sole backing indication in the sector.

Physical capability is additionally being built by companies. Sai Life Sciences spent ₹633 crore on chief expenditure in FY26. Syngene signed the first manufacturing agreement for its biologics facility at Bayview in Baltimore, in the United States, alongside a ample pharma customer, announced on 27 October 2026. Serum Institute's HPV vaccine received WHO prequalification in October 2026, which allows UN agencies to buy it. Each of those is a manufacturing, norm or regulatory hiring signal.

The traffic runs through commerce rules, and the logic is value understanding. The US imposed a 100% tariff on patented drugs under a Section 232 proclamation of 2 April 2026, productive from 31 July 2026 for the largest companies and 29 September 2026 for all others, during generics and biosimilars remain exempt for now. On 28 and 29 September the US afterward listed India among 20 countries eligible for a 0% charge on certain specialty drugs, including division and cistron therapies, according to Business Today. For Indian biotech the applicable consequence is that biosimilar and agreement activity is protected today, and that the safety is a guideline choice that can change.

9. The rules you volition activity inside

Biotechnology is among the most heavily regulated industries a alumnus can associate in India, and it is regulated by an unusually ample figure of distinct bodies: the Central Drugs Standard Control Organisation approves drugs, biologics and medicinal trials, the Department of Biotechnology's Review Committee on Genetic Manipulation oversees investigation alongside genetically engineered organisms, the Genetic Engineering Appraisal Committee under the surroundings ministry approves their release, ICMR sets ethical guidelines for investigation on people, the FSSAI governs food, and the National Biodiversity Authority governs admission to biologic resources. You do not need to memorise them. You do need to cognize which one governs the job you are applying for, since that sole fact determines your regular work, your records and your occupation ceiling.

Four regulation changes have altered what the job looks like, and all four are live correct now.

The scheme is value understanding once, since it explains most biotechnology news you volition read. A guideline sets a direction and an outlay, a division writes the detail, companies and institutions build to it, job descriptions change, and the data verify it a twelvemonth later. If you can location a news narrative on that chain, you can say item helpful concerning it.

10. What could go wrong

Read this as a catalog of things to observe fairly than reasons to remain away. Every hazard current is documented in an authoritative publication, a law resolute or regulator release, or a business filing, and most of them are also, from a occupation item of view, job descriptions. The WHO medicinal merchandise alert of October 2025 on contaminated Indian cough syrups is value study in full, since it shows exactly how a norm nonaccomplishment becomes a national regulatory event.

The hazard that biotechnology organisations name most frequently in their own results is not science. It is the client and the regulator, and specifically what happens whenever one ample client or one inspection goes the incorrect way. That is the sole most helpful item to keep in intellect whenever you difference two job offers in this sector: ask which one can motionless prosperity your squad if its largest client cuts orders for a year, since for at smallest one well-known director in FY26 it did.

11. One company's year, in detail

Biocon is the largest listed biotechnology business in India by revenue, its numbers are audited and public, and FY26 is the twelvemonth it took complete ownership of its biosimilars business. It is additionally the clearest accessible answer to the inquiry “can an Indian business build a earth biologics business”.

Biocon develops and sells biosimilars, generic formulations and energetic ingredients, and owns a interest in the agreement investigation business Syngene. FY26, the twelvemonth to 31 March 2026, is the twelvemonth it brought its biosimilars endeavor entirely in-house, and the twelvemonth its results showed the two the power of that endeavor and its cost.

What it establishes. An Indian business can build a biosimilars endeavor of additional than ₹10,000 crore a twelvemonth that sells into the most demanding markets in the world, and develop it 16% in a sole year. That is the clearest evidence in this study that Indian biotechnology can vie on complex biologics, not lone on volume. The difference alongside Syngene, which does outstanding discipline for another people's products and saw gain autumn 36% whenever one client cut back, is the most helpful item in this study to be capable to explain in an interview.

What it does not establish. One powerful biosimilars twelvemonth is not a track document of profit. Margin cut on the reported basis, gain before exceptional items is fine below the reported FY25 level, and the growth header depends on which basis you use. Say all of that if you are asked. Being capable to contend the two sides of a business you regard is different in a alumnus candidate. The company's own FY26 release is abbreviated and value study in full.

12. Latest news

The field restates itself all quarter. These are the developments from the final two quarters that have really changed something, all alongside the date it happened.

Pick one item, not all eight, and have a perspective on it. “Biocon's biosimilars grew 16% in FY26 during Syngene's gain cut 36% mostly since of one customer, which tells me that owning a merchandise and marketing a assistance are extremely distinct risks” is a improved answer than reciting the list. Interviewers are evaluation whether you read, not whether you memorise.

13. The jobs themselves

Biotechnology hires into a small figure of well-defined tracks, and the commitment is real: you volition be stated a project, an assay, a lot document or a regulatory document to own before than in many industries, since the companies are mid-sized and the compliance petition is enormous. The commerce is that the investigation path pays a fixed fellowship for years, and the industry path starts in roles that appearance regular from the outside, specified as norm control, before they guide anyplace senior.

One caveat before the tables. Exam schedules, fellowship rules and eligibility conditions alter all sequence in this sector, and DBT's fellowship path itself changes from December 2026. Always inspect the authoritative notification fairly than a coaching website, and inspect the date it was issued.

The investigation exam route, in detail

The path has multiple gates and most candidates underestimate how rivalrous the archetypal one is. In the GATE 2026 Biotechnology paper, organised by IIT Guwahati, 26,808 candidates registered, 21,513 candidates appeared and 4,124 qualified, a qualifying charge of concerning 19%. The general-category qualifying grade was 25.8 out of 100. The Life Sciences document is larger: 50,732 registered and 9,273 qualified. For graduate admission, GAT-B 2026, run by the National Testing Agency for the Regional Centre for Biotechnology, covered 1,316 DBT-sanctioned seats throughout 79 programmes, alongside a monthly stipend of ₹5,000 for an M.Sc. in biotechnology and ₹12,000 for an M.Tech.

The crucial and extensively missed detail: from December 2026, DBT's investigation fellowships are awarded through CSIR NET, under a new topic called Life Sciences and Bio-Technology. Until now they ran through a distinct exam, BET, which was final held on 17 May 2026. The December 2026 sequence of the Joint CSIR-UGC NET accepts applications until 5 November 2026, alongside the exam on 19, 22 and 27 December. GATE 2027, organised by IIT Madras, has already closed registration and volition be held in February 2027.

What the archetypal twelvemonth really looks like

Whichever path you act by, the archetypal twelvemonth is dominated by the identical thing: operating at the place or on the manufacturing floor, and documenting everything you do. Even regulatory, data and endeavor roles in fine biotechnology companies commencement near to the laboratory, and the ones that do not lean to create group who compose documents nobody in the factory can follow.

The skills that really get you hired

For the investigation route, choice is nearly entirely the exam: the GATE, CSIR NET or GAT-B syllabus, on a published form alongside published cutoffs. Preparation is a known quantity, and the highest-return move is to use to all sequence you are eligible for, since the December 2026 CSIR NET now carries DBT fellowships as well.

For everything else, three particular things pay off far additional than broad preparation. First, study fine lab and manufacturing custom properly. Most biopharma companies and CRDMOs volition test whether you comprehend documentation, deviations and data integrity, and it is the sole largest gap in caller graduates. Second, study to peruse the data the field runs on. Read the India BioEconomy Report summary, discover the section you desire to activity in, and peruse the final results publish of two companies in it. If you are targeting startups, BIRAC publishes its aid schemes and calls, which tells you what benevolent of activity is being funded correct now. Third, cognize one regulation properly, whichever one governs the role: revised Schedule M if you desire to activity in manufacturing or quality, the New Drugs and Clinical Trials Rules if you desire medicinal or regulatory work, or the GMO rules and the genome-editing exemption if you desire to activity in agri-biotech. The Life Sciences Sector Skill Development Council has developed 141 qualification packs that depict these jobs in detail.

Prepare one apparent clarification of an test or procedure you have run, and rehearse it until you can explain it to person exterior your field. Then prepared the harder version: what you would do if a outcome cut exterior specification, who you would tell, and what you would compose down. Almost all applicant prepares the archetypal and nearly none prepares the second, and the second is what a biopharma or CRDMO panel is really looking for.

14. The numbers to learn, and what to do next

Eight conditions transport particular meanings in this field and are used loosely nearly everyplace else. Knowing them exactly is the cheapest imaginable way to audio akin person who plant in biotechnology fairly than person who has peruse concerning it.

Always province the duration and the basis. “Biocon grew concerning 11% in FY26 on reported numbers, or 13% on the company's adjusted base” is a declaration nearly no applicant can say. “Biotech is booming” is a declaration anyone can say. The field publishes its bioeconomy evaluation all March and its business results all quarter, and the group who have really peruse them are a extremely small group.

What to do next. Six tangible steps, in the command they volition really help.

Every fig in this study is traceable to a authorities release, an authoritative exam study or notice, a company's own results release, a regulatory publish or a published industry report, alongside the duration stated in the text. Data is current as of 28 October 2026. The bioeconomy evaluation is published formerly a twelvemonth for the former calendar twelvemonth and business results attain quarterly, so treat item undated as environment fairly than fact. If you are study throughout this series, the FMCG type of this report uses the identical method on a extremely distinct sector, and the wider careers library covers the roles named complete in additional depth.